Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception

Deven Patel, Mario Cortina-Borja, Andrea De Maria, Marie Louise Newell, Claire Thorne

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women conceiving on highly active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor about their therapeutic management. Methods: Linear mixed models were fitted to study changes in VL and potential associated factors including HAART type or duration and immune status among 127 women receiving HAART at conception with detectable VL enrolled in the prospective European Collaborative Study. Results: Median duration of HAART at conception was 10 months. A total of 78 (61%) women conceived while on protease inhibitor (PI)-based HAART. Overall, 72 (57%) women remained on the same HAART regimen throughout pregnancy, 24 (19%) switched regimens and 31 (24%) interrupted HAART during early pregnancy. The intentionto-treat model indicated constant VL up to 10 gestational weeks; thereafter, levels decreased significantly, by 0.06 log 10 copies/ml weekly until delivery. At baseline, immune status was significantly associated with HIV RNA levels. Excluding those with treatment interruption, there was no significant difference in VL slope between women who did and did not modify their HAART regimens (P=0.14); women conceiving on non-nucleoside reverse transcriptase inhibitor-based HAART had consistently lower VL throughout pregnancy than those on PI-based HAART (P=0.02). Most (64/103, 62%) women had detectable VL within 4 weeks of delivery (median 2.40 log 10 copies/ ml). The overall mother-to-child transmission rate was 1.72% (95% confidence interval 0.21-6.1). Conclusions: Practices regarding management of women conceiving on HAART with detectable VL vary in Western Europe. The existence of this group of pregnant women highlights the need for improved monitoring of and support for treated women before they become pregnant, as well as during pregnancy.

Original languageEnglish
Pages (from-to)41-49
Number of pages9
JournalAntiviral Therapy
Volume15
Issue number1
DOIs
Publication statusPublished - 2010

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception'. Together they form a unique fingerprint.

Cite this